368 related articles for article (PubMed ID: 15827050)
41. [Extended assessment of peritoneal transport kinetics of substances and water as an important element of integrated dialysis care].
Baczyński D; Antosiewicz S; Waniewski J; Marciniak M; Wańkowicz Z
Pol Merkur Lekarski; 2004 Aug; 17(98):110-3. PubMed ID: 15603317
[TBL] [Abstract][Full Text] [Related]
42. [The peritoneal kinetic study performed with hypertonic glucose permits better evaluation of UF capacity and determination of sieving of sodium].
Fernández-Reyes MJ; Bajo Rubio MA; del Peso Gilzanz G; Estrada P; Sousa S; Sánchez-Villanueva R; Heras M; Ossorio M; Sánchez-Vega C; Selgas R
Nefrologia; 2010; 30(2):208-13. PubMed ID: 20393620
[TBL] [Abstract][Full Text] [Related]
43. Peritoneal fast transport in incident peritoneal dialysis patients is not consistently associated with systemic inflammation.
Rodrigues AS; Almeida M; Fonseca I; Martins M; Carvalho MJ; Silva F; Correia C; Santos MJ; Cabrita A
Nephrol Dial Transplant; 2006 Mar; 21(3):763-9. PubMed ID: 16332703
[TBL] [Abstract][Full Text] [Related]
44. Long-term follow-up of body size indices, residual renal function, and peritoneal transport characteristics in continuous ambulatory peritoneal dialysis.
Twardowski ZJ; Moore HL; Prowant BF; Satalowich R
Adv Perit Dial; 2009; 25():155-64. PubMed ID: 19886338
[TBL] [Abstract][Full Text] [Related]
45. Increased subcutaneous insulin requirements in diabetic patients recently commenced on peritoneal dialysis.
Szeto CC; Chow KM; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
Nephrol Dial Transplant; 2007 Jun; 22(6):1697-702. PubMed ID: 17259649
[TBL] [Abstract][Full Text] [Related]
46. Peritoneal transport status influence on atherosclerosis/inflammation in CAPD patients.
Sezer S; Tutal E; Arat Z; Akçay A; Celik H; Ozdemir FN; Haberal M
J Ren Nutr; 2005 Oct; 15(4):427-34. PubMed ID: 16198934
[TBL] [Abstract][Full Text] [Related]
47. Evolution of clinical parameters and peritoneal function in a cohort of CAPD patients followed over 7 years.
Faller B; Lameire N
Nephrol Dial Transplant; 1994; 9(3):280-6. PubMed ID: 8052436
[TBL] [Abstract][Full Text] [Related]
48. Peritoneal transport evaluation in peritonitis: comparison between methods.
Borràs M; Teixidó J; Galimany R; Biosca C; Montoliu J
Adv Perit Dial; 1995; 11():145-8. PubMed ID: 8534689
[TBL] [Abstract][Full Text] [Related]
49. [Effects of nitroprusside and vibration on peritoneal transport of solutes in continuous ambulatory peritoneal dialysis patients].
Tan XY; Liu FY; Duan SB
Hunan Yi Ke Da Xue Xue Bao; 2000 Aug; 25(4):357-60. PubMed ID: 12206001
[TBL] [Abstract][Full Text] [Related]
50. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Nishina M; Endoh M; Suzuki D; Tanabe R; Endoh H; Hirahara I; Sakai H
Clin Exp Nephrol; 2004 Dec; 8(4):339-43. PubMed ID: 15619033
[TBL] [Abstract][Full Text] [Related]
51. Peritoneal kinetics of cancer antigen 125 in peritoneal dialysis patients: the relationship with peritoneal outcome.
Jiménez C; Díaz C; Selgas R; Auxiliadora Bajo M; del Peso G; Sánchez-Tomero JA; Gonzalez-Gancedo P
Adv Perit Dial; 1999; 15():36-9. PubMed ID: 10682069
[TBL] [Abstract][Full Text] [Related]
52. High-transport membrane is a risk factor for encapsulating peritoneal sclerosis developing after long-term continuous ambulatory peritoneal dialysis treatment.
Yamamoto R; Nakayama M; Hasegawa T; Miwako N; Yamamoto H; Yokoyami K; Ikeda M; Kato N; Hayakawa H; Takahashi H; Otsuka Y; Kawaguchi Y; Hosoya T
Adv Perit Dial; 2002; 18():131-4. PubMed ID: 12402604
[TBL] [Abstract][Full Text] [Related]
53. [Evaluation of peritoneal solute transport parameters in diabetics treated with continuous ambulatory peritoneal dialysis].
Baczyński D; Marciniak M; Olszowska A; Waniewski J; Weryński A; Wańkowicz Z
Pol Merkur Lekarski; 1998 Nov; 5(29):274-6. PubMed ID: 10101499
[TBL] [Abstract][Full Text] [Related]
54. Serum cystatin C: a surrogate marker for the characteristics of peritoneal membrane in dialysis patients.
Al-Wakeel JS; Hammad D; Memon NA; Tarif N; Shah I; Chaudhary A
Saudi J Kidney Dis Transpl; 2009 Mar; 20(2):227-31. PubMed ID: 19237809
[TBL] [Abstract][Full Text] [Related]
55. Hypokalaemia: an independent risk factor of Enterobacteriaceae peritonitis in CAPD patients.
Chuang YW; Shu KH; Yu TM; Cheng CH; Chen CH
Nephrol Dial Transplant; 2009 May; 24(5):1603-8. PubMed ID: 19103738
[TBL] [Abstract][Full Text] [Related]
56. Increased peritoneal solute transport in diabetic peritoneal dialysis patients.
Lin JJ; Wadhwa NK; Suh H; Cabralda T; Patlak CS
Adv Perit Dial; 1995; 11():63-6. PubMed ID: 8534740
[TBL] [Abstract][Full Text] [Related]
57. Peritoneal function and adequacy calculations: current programs versus PD Adequest 2.0.
Teixidó-Planas J
Perit Dial Int; 2002; 22(3):386-93. PubMed ID: 12227398
[TBL] [Abstract][Full Text] [Related]
58. Peritoneal protein losses in diabetic patients starting peritoneal dialysis: is there a relationship with diabetic vascular lesions?
Coronel F; Cigarrán S; Herrero JA; Delgado J; Ramos F; Gomis A
Adv Perit Dial; 2009; 25():115-8. PubMed ID: 19886331
[TBL] [Abstract][Full Text] [Related]
59. Changes in peritoneal membrane transport rates in patients on long term CAPD.
Blake PG; Abraham G; Sombolos K; Izatt S; Weissgarten J; Ayiomamitis A; Oreopoulos DG
Adv Perit Dial; 1989; 5():3-7. PubMed ID: 2577421
[TBL] [Abstract][Full Text] [Related]
60. The effect of calcium antagonists on the peritoneal membrane in patients on CAPD.
Vargemezis V; Pasadakis P; Thodis E
Adv Perit Dial; 1989; 5():8-11. PubMed ID: 2577433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
